Celiac disease in the Red Sea state of Sudan

Ali K Ageep

ABSTRACT

Background and aim: Celiac disease is characterized by sensitivity to gluten that results in inflammation and atrophy of the small intestine mucosa. The aim of this research was to document the presence of celiac disease and to describe its clinical presentations in the tribes living in the Red Sea state of Sudan.

Methods: 172 patients suspected to have celiac disease, were examined at the Red Sea Medical Center laboratory, Port Sudan, Sudan, from August 2008 to September 2011. All clinical data was collected using questionnaires. Serum samples were obtained from all patients for serological detection of anti-gliadin (AG) and anti-tissue transglutamase (ATTG) antibodies (IgG and IgA) using the enzyme-linked immuno-sorbent assay (ELISA).

Results: 128 patients were found to have celiac disease. The commonest presenting symptom was chronic diarrhea (20.3%) followed by weight loss (14%). Males and females were nearly equally affected. All age groups were affected with a peak incidence between 5 to 10 years.

Conclusions: Celiac disease occurs in the Red Sea state and may well be under-diagnosed. The combination of IgA AGA and IgA ATTG tests represent a good diagnostic method to confirm celiac disease in suspected cases. Special attention needs to be given to methods that encourage adherence to gluten-free diet in affected people in this region.

KEYWORDS: celiac disease, gluten, anti-tissue transglutamase, Port Sudan

Introduction

Celiac disease (CD) is a hereditary intolerance to gluten, a protein found in wheat and to a lesser extent in barley, rye and oat. Its prevalence has been underestimated, but it is now considered one of the most common genetic disorders in the West with a prevalence of 1-2.67%.1-3 The clinical manifestations are a manifestation of malabsorption and include symptoms of diarrhea, steatorrhea and nutritional and vitamin deficiencies. Secondary immunologic illnesses, such as atopic dermatitis, dermatitis herpetiformis, alopecia and aphthous ulcers may be the primary presentation.4 The disease is diagnosed in about 10% of first degree relatives of an individual with celiac disease.5 Although hereditary factors play a significant role, genetic factors alone do not explain the development of the disease because the disease is concordant in only 60 to 70% of identical twins.6 All people with HLA DQ2 and DQ8 alleles do not develop the disease and others without these alleles have been observed to develop celiac disease, thus indicating involvement of hitherto uncharacterized genes. Additional factors such as hormones and infectious agents may also be putative in triggering aberrant interactions between ingested gluten and the host’s mucosal immune system, thereby establishing a chronic inflammatory reaction in the intestines of genetically predisposed individuals.6 The prevalence of clinically diagnosed disease is 0.05–0.27% in various studies.7
However, population studies from parts of Europe, India, South America, Australasia and the USA (based on serology and histopathology) indicate that the prevalence may be between 0.33 and 1.06% in children (5.66% in one study of Sahrawi children)\(^7\) and 0.18–1.2% in adults.\(^8\) The earliest described patients of celiac disease in Sudan were reported by Suliman in 1978,\(^9\) but no data concerning the prevalence of the disease in Sudan or its Red Sea state is available till date.

This is the first study which documents the presence of celiac disease among different tribes in Eastern Sudan. The primary aim of this research was to confirm the presence of celiac disease in the Red Sea state of Sudan. This data will help sensitize our local health staff towards celiac disease, thus encouraging delivery of appropriate clinical management and health care facilities to these patients. We have also attempted to discuss the varying clinical presentations of the disease in our study.

**Methods**

One hundred and seventy two patients suspected to have celiac disease were examined at the Red Sea Medical Center laboratory, Port Sudan, Sudan, from August 2008 to September 2011. As per the 2002 national census the region has a total population of 739,300, after adjusted growth rates. Five main tribes exist in this area. The population distribution of these tribes is as follow: 43% Hadandwa, 28% Benne Ammer, 5% Rashayda, 19% Northern Sudan tribes and 5% Western Sudan tribes.

All clinical and epidemiological data including age, sex, presenting complaints and the tribe characteristics were collected using questionnaires. Ethical clearance of this study was obtained from the regional Ethical Review Committee (ERC).

Serum samples were obtained from all patients for serological detection of anti-gliadin and anti-tissue transglutamase antibodies (IgG and IgA) using a customized enzyme-linked immuno-sorbent assay (ELISA) (EUROIMMUN Medizinische Labordiagnostika AG). The assays were carried out as per the manufacturer’s instructions. Briefly, patient sera were first diluted 1:20 in sample buffer. A 100 µl each of the calibrators, negative controls, positive controls and diluted samples were next transferred into the individual microplate wells and then incubated for 30 minutes. Subsequently the wells were emptied and washed three times using 300 µl of working strength wash buffer for each well. Thereafter 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgG) was added to each well and incubated for another 30 minutes. Post incubation the same washing procedure was repeated, followed by addition of 100 µl of chromogen/substrate solution to each well and 15 minutes of incubation in the dark. Finally 100 µl of stop solution was added to each well in the same order and at the same speed as the substrate solution was introduced. Photometric measurement of color intensity was recorded by an ELISA reader at a wavelength of 450 nm within 30 minutes of adding the stop solution. The cut-off value of the test was 20 RU/ml.

**Statistical analysis**

Data were analyzed by using the Statistical Package for Social Sciences (SPSS) version 16.0 and results were compiled as frequencies and percentages.

**Table 1:** Shows the clinical presentations of celiac disease in the different sex and age groups

<table>
<thead>
<tr>
<th>Presenting complaint</th>
<th>Males</th>
<th>Females</th>
<th>&lt;5 years</th>
<th>5-10 years</th>
<th>10-20 years</th>
<th>20-30 years</th>
<th>30-50 years</th>
<th>50-60 years</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic diarrhea</td>
<td>12</td>
<td>14</td>
<td>8</td>
<td>10</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>26 (20.3)</td>
</tr>
<tr>
<td>Weight loss</td>
<td>10</td>
<td>8</td>
<td>7</td>
<td>10</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>18 (14.0)</td>
</tr>
<tr>
<td>Flatulence, abdominal distention</td>
<td>7</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13 (10.1)</td>
</tr>
<tr>
<td>Foul-smelling stools</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>8 (6.3)</td>
</tr>
<tr>
<td>Stomach pain, gas, and bloating</td>
<td>3</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>7 (5.5)</td>
</tr>
<tr>
<td>Stunted growth</td>
<td>10</td>
<td>7</td>
<td>7</td>
<td>8</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>17 (13.3)</td>
</tr>
<tr>
<td>Bone or joint pain</td>
<td>5</td>
<td>7</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>12 (9.4)</td>
</tr>
<tr>
<td>Anemia</td>
<td>7</td>
<td>7</td>
<td>6</td>
<td>7</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>14 (10.9)</td>
</tr>
<tr>
<td>Skin manifestations</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>8 (6.3)</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>3 (2.3)</td>
</tr>
<tr>
<td>Infertility</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2 (1.6)</td>
</tr>
</tbody>
</table>

**Notes:** Some patients presented with more than one symptom, but in this table the major complaint has been recorded. The figures denote number of patients.
A patient was considered positive for celiac disease when the titer of anti-TTG and AG antibodies was found to be more than 10 times of the cut-off values.10-11

**Results**

Out of the 172 patients investigated for celiac disease, only 128 patients were confirmed positive for celiac disease. The remaining forty four negative patients were excluded from further analysis. The titers of antibodies were higher in the anti-tissue transglutamase tests than the anti-gliadin tests. The commonest presenting symptom was chronic diarrhea (20.3%) followed by weight loss (14%) (Table 1). The third common presentation was noted to be stunted growth (13.3%). Males and females were nearly equally affected (M:F = 1:0.97). All age groups were affected with a peak incidence between 5 to 10 years (41.4%). Table 2 illustrates that the overwhelming majority of celiac disease is among the Benne Amir tribe (63.3%), followed by the Hadandwa tribe (14.1%) and the Northern Sudan tribes (12.5%).

**Discussion**

Until the 1990s the presence of celiac disease in Sudan was considered low. However, with the introduction of assays for anti-tissue transglutamase antibodies (ATTGA) and anti-gliadin antibodies (AGA) CD has been more readily detected and reported from Sudan.12 To our knowledge, this is the first study which documents the presence of CD in the Red Sea state of Sudan.

The clinical presentation of CD varies from silent disease to full-fledged severe intestinal and extra-intestinal manifestations.12,13 In this study, chronic diarrhea was the most common presenting symptom (20.3%). In Iran, Lebanon, Iraq, Saudi Arabia and Kuwait, CD has been reported to be one of the most common causes of chronic diarrhea.14-16 This is almost similar to our findings. The second common symptom was weight loss (14%). In Egypt 4.7% of children presenting with diarrhea and weight loss had CD.17 The variation in the prevalence of clinical manifestations of CD across different studies, may be due to the low number of patients evaluated or a delay in their presentation. Stunted growth represents the third most common presenting complaint (13.3%). The highest prevalence of stunted growth was reported from Jordan where 26% of children with CD had rickets.18 In Turkey 51% of patients had a height <2.5 standard deviations below the mean.18 About one third of children with CD in Western countries develop short stature.19 Anemia was noted in 10.9 % of the patients, and it was mainly due to iron deficiency in most of the cases. Worldwide prevalence of CD among patients with iron deficiency anemia is 2.8-8.7% and may be as high as 15%.20,21 Folate and B12 deficiency may contribute to anemia in CD, and surprisingly, anemia of chronic disease is relatively common.22 The diagnosis of CD was confirmed by serological detection of the AGA and ATTGA. Tissue transglutamase IgA sensitivity is 70%-100%,23,24 and its specificity is 99%.24 The sensitivity of IgA AGA is about 80%, while that of IgG AGA is 90-100%.25,26 Endoscopic intestinal biopsy was not available in the region. Only one case of villous atrophy was diagnosed by a visiting gastroenterologist. Duodenal biopsy remains the gold standard for celiac disease (CD) diagnosis. However, it has several pitfalls and requires an invasive procedure even in children. In the past few years a more prominent role for a definitive diagnosis based solely on serology has been proposed. The predictive value of high levels of anti-tissue transglutamase antibodies has also been reported in retrospective CD cohorts. Based on these studies, some authors have proposed to start a gluten-free diet (GFD) for patients with high ATTG antibody levels, without a duodenal biopsy.11 Thus high levels of the serological markers remain the test of choice for detection of CD in our study region.

We believe that the prevalence of CD in the Red Sea state may be underestimated due to lack of awareness and low suspicion of the disease. Unfortunately, some doctors, especially in the rural areas, still do not know when to suspect celiac disease. Many physicians still do not realize there is no “typical” celiac disease patient. Celiac disease can begin at any age, persists for life and can affect multiple organs. People with celiac disease can be thin, obese or have normal weight. In both children and adults the symptoms of celiac disease can be extremely variable or there may be no symptoms at all. Unfortunately owing to the heterogeneity in the clinical
Celiac disease may take up to 2 years in some individuals. Factors such as hormones and infectious agents may also be involved in the disease pathophysiology. Additional factors such as hormones and infectious agents may also be involved in the disease pathophysiology. The staple diet in this area constitutes mainly of sorghum. A combined effort on the part of health care workers and researchers to increase health education and help elucidate the specific risk factors for CD in this region are highly recommended.

Currently the only treatment for celiac disease is a gluten-free diet. Dietary avoidance of gluten leads to symptom improvement in 70% of patients within 2 weeks. However, complete histological resolution of small bowel inflammation may take up to 2 years in some individuals. It can be a challenge to avoid gluten in eastern Sudan. Poverty and ignorance are the major obstacles in such developing regions. As the pathophysiology of celiac disease gets clearer, new methods of treatment are being developed including orally active drugs.

Conclusions

Celiac disease occurs in the Red State and may well be under-diagnosed. The combination of AGA IgG and ATTG IgA tests represents a good diagnostic method for diagnosis of suspected cases of celiac disease. Special attention needs to be given to methods that encourage adherence to gluten-free diet in affected people in this region. Large prospective studies are needed to assess the true incidence, the clinical course, the efficacy of treatment modalities employed, patient compliance, disease complications and response to treatment in eastern Sudan.

References